story-header-labs-testing

About Us

We are a team of award-winning scientists with a mission to empower individuals to make better-informed decisions about their skin health.

Sequential Skin is the result of the founders’ passion for molecular genetics.

Sequential Skin was born from scientific research and discovery for the purpose of bettering people’s chances of having healthy skin without going through the trial and error process of discovering what their skin’s needs truly are.

 

We have spent years developing the most innovative adhesive patch to collect skin samples that can be analyzed most effectively.


Leadership

Our microbiome test is the most comprehensive test on the market. We use a method known as quantitative real-time PCR (qPCR) that looks at specific markers in your skin microbiome and how they impact your skin. Our microbiome markers were generated in an ISO 13485 (medical devices) and CAP-accredited lab, ensuring our results' quality, accuracy, and reliability.

 

Every single one of the samples that we receive is studied in our lab at the hands of the industry’s top scientific minds and is handled with care and the utmost discretion. Based on the analysis, a comprehensive report is compiled and shared with the hope to introduce skincare beyond you and what the eye can see. 

Dr. Oliver Worsley
CEO & CO-FOUNDER
Dr. Albert Dashi
CHIEF SCIENCE OFFICER & CO-FOUNDER
Petronille Houdart, PharmD
SKINCARE DIRECTOR

Trusted by dermatologists

Sequential Skin’s test is to pioneer a next-generation skin microbiome test to be able to help with identification, analysis and early-stratification of the skin microbiome.  It’s known the skin microbiome is dysbalanced in certain people, and so understanding the progression of skin microbiome colonization between healthy skin and skin traits is paramount.

Further research and studies in the skin microbiome field is much needed and the Sequential Skin team is pivotal in this respect. The team is interrogating the skin microbiome for its potential to find new ways to improve the health of the skin.

DR NATALYA FOX, DERMATOLOGIST,
NHS (EPSOM AND ST HELIER UNIVERSITY HOSPITALS)
MBCHB UNIVERSITY OF EDINBURGH 2014, FULL MRCP (UK)
DR LUSHEN PILLAY, HEAD OF DERMATOLOGY 
MD WITS UNIVERSITY, SOUTH AFRICA

Board of Advisors

Dr Alexander Lezhava.png

Dr Alexander

Lezhava

Our advisors are world leaders in the skin microbiome and have extensive experience in bringing forward solutions for skin concerns

Dr Lushen Pillay.jpg

Dr Lushen Pillay

Dr Natalya Fox

ss-headshot-advisor-elena.png

Prof. Elena Lurie-Luke

ss-headshot-advisor-niranjan.png

Prof. Niranjan Nagarajan

ss-headshot-advisor-tom.png

Prof. Tom Dawson

Please find listed a selection of relevant peer-reviewed publications from our advisors.

  • Wu G, TL Dawson, et al. (2015) Genus-Wide Comparative Genomics of Malassezia Delineates Its Phylogeny, Physiology, and Niche Adaptation on Human Skin. PLOS Genetics 11(11): e1005614.
     

  • Chng, K., Nagarajan, N., et al. (2016) Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare. Nat Microbiol 1, 16106.
     

  • Tay, A.S., Nagarajan, N., et al (2018). 1039 Skin microbiome profiles of atopic dermatitis patients segregate into two community composition types that are stable before and after therapy. Journal of Investigative Dermatology. 138. S176. 10.1016/j.jid.2018.03.1051.
     

  • Ramasamy S., Barnard, E., Dawson, TL, and Huiying Li. (2019). Role of the skin microbiota in acne pathophysiology. British Journal of Dermatology, https://doi.org/10.1111/bjd.18230.

  • Dawson, TL. (2019) Malassezia: The Forbidden Kingdom Opens. Cell Host Microbe https://doi.org/10.1016/j.chom.2019.02.010
     

  • Tay, A.S., Nagarajan, N., et al (2020). Atopic dermatitis microbiomes stratify into ecologic dermotypes enabling microbial virulence and disease severity. The Journal of allergy and clinical immunology. 10.1016/j.jaci.2020.09.031.
     

  • Dawson, TL. (2021) Malassezia: A Skin Commensal Yeast Impacting Both Health and Disease. Front. Cell. Infect. Microbiol., doi.org/10.3389/fcimb.2021.659219